Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial
Ou J, Smith RC, Tobe RH, Lin J, Arriaza J, Fahey JW, Liu R, Zeng Y, Liu Y, Huang L, Shen Y, Li Y, Cheng D, Cornblatt B, Davis JM, Zhao J, Wu R, Jin H
Journal of autism and developmental disorders · 22 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Natural Science Foundation of China
- Gobierno
- Natural Science Foundation of Hunan Province
- Gobierno
- National Key Research and Development Program of China
- Gobierno
- National Key R&D Program of China
- Organización sin fines de lucro
- Davis family funding
- Gobierno
- National Key R&D Program of China
- Subvenciones
- National Natural Science Foundation of China (81974217); Natural Science Foundation of Hunan Province (2020JJ5825); National Key Research and Development Program of China (2016YFC1306900); National Natural Science Foundation of China (81622018)
Según 6 financiadores declarados.
Publicación
- Publicado
- 2022-11-24 · J Autism Dev Disord · vol. 54 · número 2 · págs. 628–641
- Editorial
- Springer Science+Business Media
- Citado
- 29 citas · más que el 91% de estudios similares · 2.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 39 trabajos
- Acceso
- De pago
- Áreas de investigación
- Autism Spectrum Disorder Research · Genetics and Neurodevelopmental Disorders · Child Nutrition and Feeding Issues
- Palabras clave
- sulforaphane, autism spectrum disorder, children, dietary supplementation, core symptoms, clinician-rated scales, treatment efficacy, safety and tolerability, intelligence level
- MeSH
- humans, isothiocyanates, sulfoxides, treatment outcome, double-blind method, child, child, preschool, autism spectrum disorder
18 autores
- Jianjun Ou🇨🇳Central South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Robert C. Smith🇺🇸Nathan Kline Institute for Psychiatric Research; NYU Langone Health; New York University
- Russell H. Tobe🇺🇸Nathan Kline Institute for Psychiatric Research; Columbia University
- Jingjing Lin🇨🇳Central South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Jen Arriaza🇺🇸New York University
- Jed W. Fahey🇺🇸Johns Hopkins University
- Ruiting Liu🇨🇳Central South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Ying Zeng🇨🇳Central South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Yanan Liu🇨🇳Central South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Lian Huang🇨🇳Central South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Yidong Shen🇨🇳Central South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Yamin Li🇨🇳Central South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Daomeng Cheng🇨🇳Guangzhou Medical University
- Brian S. Cornblatt🇺🇸Nutramax Laboratories (United States)
- John M. Davis🇺🇸University of Illinois Chicago
- Jingping Zhao🇨🇳 · autor de correspondenciaCentral South University; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Renrong Wu🇨🇳 · autor de correspondenciaCentral South University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences; Second Xiangya Hospital of Central South University; Hunan Institute of Mental Health
- Hua Jin🇺🇸 · autor de correspondenciaUniversity of California San Diego; VA San Diego Healthcare System
Resumen
El texto original del estudio, en el idioma en que se publicó.
Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N = 108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.